November 23, 2015 5:42pm

All eyes are fixed on the declared merger of Pfizer PFE -3.23%, Inc. and Allergan AGN -2.97% plc, which have the impact of an inversion, and the questions quickly become: Is it a game changer, a challenge to Treasury’s new tax inversion guidelines, or just riveting financial drama? However, there is a different sort of healthcare drama that is playing out that is even more important to the drug industry’s bottom line. You see, for seven hours on Friday, experts in the pharmaceutical industry, including Merck & Co MRK -1.89%., Inc., Novartis International AG and Express Scripts ESRX +0.82% Holding Company, as well as HHS and Medicare officials, the insurance lobby and Kaiser Permanente, debated the sustainability of skyrocketing drug pricing.


Members only. Please login.